عنوان

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.

شماره

LA1bm7h0tr

عنوان اصلي

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.

نام عام مواد

[Article]

نام نخستين پديدآور

Jardim, Denis L Fontes; de Melo Gagliato, Debora; Falchook, Gerald S; Janku, Filip; Zinner, Ralph; Wheler, Jennifer J; Subbiah, Vivek; Piha-Paul, Sarina A; Fu, Siqing; et al.

متن يادداشت

We sought to investigate the demographics and tumor-associated features in patients with gastroesophageal (GE) malignancies referred to our Phase I Program who had formalin-fixed, paraffin-embedded tissue from archival or new biopsies tested for MET mutation and/or amplification. MET amplification was found in 5 of 76 (6.6%) patients (3/34 [8.8%] esophageal, 2/26 [7.7%] gastric and none in 22 gastroesophageal junction cancers). The only MET mutation detected in 3 of 41 (7.3%) patients was N375S. No demographic and histologic characteristics were associated with specific MET abnormalities. Median overall survival was 3 and 5 months for patients with and without a MET alteration, respectively (hazard ratio [HR] = 2.1; 95% CI, 0.8 to 5.5; P=.14). Sixteen of 81 (20%) patients were enrolled in a c-MET inhibitor trial. Best responses were stable disease in 3 patients (19%), including a patient with esophageal adenocarcinoma that remained on the trial for 9.9 months (wild-type for MET abnormality). All tumors with MET abnormality (n=3) progressed on a c-MET inhibitor in fewer than 2 months. In conclusion, MET abnormalities can be found in a small group of patients with GE adenocarcinoma and further studies are necessary to better characterize the prognostic and predictive impact of MET alterations.

تاريخ نشر

2014

عنوان

UC San Diego

نام الکترونيکي

نوع ماده

[Article]

کد کاربرگه

275578

سطح دسترسي

a

تكميل شده

Y